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Abstract 
Background: Ambulatory measurement of intrathoracic impedance (ITI) with an 
implanted device has potential to assess fluid accumulation in patients with heart failure 
(HF), but it has failed to reduce HF-related hospitalization because of a high false-
positive rate. 
Objective: We aimed to examine whether a modified algorithm (OptiVol 2.0) could 
reduce false-positive HF events documented in our multicenter trial (MOMOTARO). 
Methods: The MOMOTARO trial assessed the potential that fluid index could predict 
fluid accumulation and therefore HF. The MOMOTARO trial assessed whether HF 
events could be detected based on fluid accumulation as assessed by fluid index. We re-
analyzed raw data of ITI trends of the threshold-crossing events with the modified 
algorithm. 
Results: The study consisted of 195 patients who had been implanted with a high-
energy device. During a mean follow-up period of 658 ± 165 days, there were 154 
primary HF events detected by the previous algorithm (OptiVol 1.0). With the previous 
algorithm, there was no significant difference in log concentration of brain natriuretic 
peptide (BNP) between baseline and alert (p = 0.21). Among 150 alerts of the previous 
algorithm, only 37 reached the threshold by the modified algorithm, and log BNP was 
significantly higher in these 37 events compared with the baseline value (2.40 ± 0.46 vs. 
2.27 ± 0.52, p < 0.01). 
Conclusion: Our simulation study demonstrates that fluid index calculated with the 
modified algorithm reduces the number of false-positive threshold-crossing HF events 
and is promising for accurate diagnosis of fluid accumulation in patients. 
Introduction 
Heart failure (HF) is associated with frequent hospitalizations and has become one of 
the largest medical problems worldwide [1]. Identifying patients at risk for 
hospitalization would be extremely helpful for reducing HF-related hospitalization. 
Symptoms such as exertional dyspnea or fatigue are unspecific, and daily measurement 
of body weight is not sensitive enough to predict clinical deterioration [2-4]. 
Intrathoracic electrical impedance (ITI) is another potentially interesting biomarker that 
can be measured safely by an implantable device. This measure has potential to 
diagnose worsening HF before symptoms of HF appear [5], but whether it can reduce 
HF hospitalization remains a controversial issue. A previous study demonstrated the low 
sensitivity (60%) and positive predictive value (60%) of this system for predicting the 
deterioration of HF [6]. Conraads et al. reported a positive predictive value of 38.1% for 
this approach [7]. A diagnostic outcome trial for HF (DOT-HF) indicated that the use of 
OptiVol alert (Medtronic, Dublin, Ireland) to measure ITI with an audible patient alert 
did not improve outcome in HF patients [8]. It increased HF hospitalizations and 
outpatient visits because of a high frequency of false-positive alerts. In a previous 
multicenter trial called MOMOTARO (Monitoring and Management of OptiVol Alert to 
Reduce Heart Failure Hospitalization), we also found a high frequency of alert events 
that were not associated with an increase in the concentration of serum brain natriuretic 
peptide (BNP) level compared with the baseline value [9]. We reduced the false-positive 
alerts by adding a criterion specifying that the alert be triggered only when ITI 
decreases by ≥4% from baseline. 
The previous OptiVol algorithm (OptiVol 1.0) that is used to calculate fluid 
index has been modified and is now referred to as OptiVol 2.0, which improves the 
ability to track ITI changes. The modified algorithm added the following improvements: 
the calculation of reference impedance and fluid index, temporal accumulation limit. 
Thus, in patients with high day-to-day variability in ITI values, the modified algorithm 
accumulates fluid index information less aggressively than the previous algorithm, 
especially for the initial period of an event. This improvement is expected to reduce the 
false-positive alerts for more precise diagnosis of worsening HF. However, it is 
unknown whether OptiVol 2.0 could reduce false-positive alerts that were detected by 
the previous algorithm. To resolve this clinical issue, we conducted a simulation in 
which raw ITI data for all alert events detected by the previous algorithm in the 
MOMOTARO trial were re-analyzed with OptiVol 2.0. We examined whether OptiVol 
2.0 could indeed reduce the false-positive alerts in comparison with BNP levels and 
other laboratory and echocardiographic parameters of HF. 
Methods 
The design and main results of the MOMOTARO study have been published 
[9]. The MOMOTARO study was a prospective observational study that was carried out 
in 12 medical centers to study whether the OptiVol alert can diagnose early stages of 
HF, which we defined as an increase in BNP. 
Patients included in this study 
Data from the 195 MOMOTARO HF patients with either preserved or reduced 
left ventricular ejection fraction (LVEF) were included in this study. All of these 
patients had undergone cardioverter defibrillator implantation or cardiac 
resynchronization therapy with cardioverter defibrillator implantation for the purpose of 
monitoring ITI. All implanted devices used the previous algorithm (OptiVol 1.0; Model 
7297, 7303, 7277, 7289, or C154DWK). Data for patients who had a device implanted 
for the first time during the initial trial as well as those with existing devices were 
included in this study. For the former cases, there was at least a one-month waiting 
period to allow postoperative clinical stabilization, resolution of pocket edema, and 
automatic calibration of the impedance reference. We excluded patients who were <18 
years old, scheduled for or had undergone cardiac surgery in the last 90 days, and those 
who were listed for heart transplantation. Further exclusion criteria were moderate-
severe chronic obstructive lung disease (forced expiratory volume <1.0 L/s), life 
expectancy <1 year, hemodialysis, primary pulmonary hypertension, and pregnancy or 
breastfeeding. All patients gave their written informed consent, and the study protocol 
was approved by the Institutional Review Board and/or Medical Ethics Committee of 
each center. 
Analysis and storage of ITI data 
Fluid status monitoring with OptiVol was based on calculations of the average 
daily ITI values measured between the right ventricular defibrillation electrode and the 
device case. Temporal changes in ITI values were compared with the reference 
impedance, which was derived from a moving average algorithm, to assess fluid status. 
When daily impedance values consistently fell below the reference, the differences were 
accumulated to generate the OptiVol fluid index. When this index exceeded a threshold 
of 60, the OptiVol alert was sent to the analysis center (Okayama University). The 
audible patient alert was turned off for the trial. All device-based diagnostic 
information, including fluid index, heart rate, heart rate variability, and patient’s activity, 
was also sent by a wireless remote monitoring system (Medtronic CareLink network). 
Primary and secondary endpoints 
Whenever a threshold-crossing event was noted on the remote monitoring 
system, the protocol required patient-physician contact within 3 days. Patients 
underwent clinical evaluation, laboratory tests, chest X-ray, 12-lead electrocardiogram, 
and echocardiography in an outpatient clinic. The primary endpoint was serum log BNP 
levels at the OptiVol alert in comparison with those at baseline. The secondary 
endpoints included the other laboratory and echocardiographic parameters between 
OptiVol alert and baseline. If the patient showed decompensated HF, they were treated 
according to a standardized treatment protocol. 
Simulation of fluid index with modified algorithm 
The OptiVol 2.0 index was calculated from the raw ITI data collected in the 
MOMOTARO study by a calculation algorithm with use of Microsoft Excel 2010 
software. We examined if the calculated OptiVol 2.0 index values in a simulation 
reached threshold at the same frequency as the OptiVol 1.0 alert events. Then, the 
OptiVol 1.0 alert events from the MOMOTARO study were divided into two groups—
those for which the calculated OptiVol 2.0 index also reached threshold (OptiVol 2.0 
positive group), and those for which the calculated OptiVol 2.0 index did not reach the 
threshold (OptiVol 2.0 negative group). We then compared the changes in log BNP 
values and of laboratory and echocardiographic parameters at threshold-crossing events 
in the two groups. 
We also analyzed the reproducibility of the OptiVol 2.0 simulation with data 
from 50 randomly selected patients. We compared the fluid index values between the 
original (OptiVol 1.0) and simulated (OptiVol 2.0) data. 
ITI trends associated with false-positive events 
In the previous study, we found three ITI trends that were likely associated with 
false-positive threshold-crossing events based on the previous algorithm (OptiVol 1.0) 
(Fig. 1), namely “cross to reference” (Fig. 1A), “spontaneous recovery” (Fig. 1B), and 
“temporary elevation” (Fig. 1C) patterns in relation to the reference line [9]. In the 
“cross to reference” pattern, the ITI crosses the reference line several times, but the 
accumulated fluid index is not canceled and the integral of the difference between 
reference and ITI finally reaches the threshold. In the “spontaneous recovery” pattern, 
ITI is below the reference curve for several days and spontaneously recovers to 
baseline, but the integral of the difference between reference and ITI reaches the 
threshold before the recovery. In the “temporary elevation” pattern, a temporary 
increase in ITI is associated with an upward deviation of the reference curve. We 
examined whether OptiVol 2.0 could exclude these false-positive patterns. 
Statistical analysis 
The Statistical Product and Service Solutions Statistics package, version 20 
(IBM Inc., Chicago, IL, USA), was used for all statistical analyses. Continuous data are 
expressed as the mean ± standard deviation, and categorical data are expressed as the 
percentage. BNP data were also log transformed because the distribution pattern of 
plasma BNP values did not appear to be normal (i.e. the data were skewed) [10]. The 
change in the measured value between baseline and OptiVol alert or during regular 
examination for each factor was evaluated by the paired t-test, and differences with p < 
0.05 were considered to be significant. Nonparametric 2 test was used to assess 
whether there was a reduction in any false-positive pattern, and p < 0.05 was considered 
statistically significant. Pearson's correlation was used to assess the simulation software 
accuracy. 
Results 
Patient characteristics at baseline 
From April 2010 to August 2011, 200 patients in 12 institutes were enrolled in 
the MOMOTARO study. Five patients were excluded according to the exclusion 
criteria. Mean age was 66.3 ± 11.3 years, and there were 149 male patients (76.4%). 
Mean LVEF was 44.3 ± 14.3%, and mean BNP was 254 ± 275 mg/dl. Patient 
characteristics are listed in Table 1. 
Threshold-crossing events by the previous algorithm 
Figure 2 shows simulated fluid index trends as detected with OptiVol 1.0 and 
OptiVol 2.0. With OptiVol 1.0, there were three types of threshold-crossing events. 
Because ITI crossed the reference line in the first two types of events, the accumulated 
difference between reference and real ITI values reached the threshold value. With 
OptiVol 2.0, only the last type of event was associated with threshold crossing (Fig. 2). 
During the mean follow-up period of 658 days (range: 102–731 days), there 
were 154 primary threshold-crossing events. We successfully simulated fluid index 
trends from the raw ITI data with OptiVol 2.0 for 150 (97%) of the events. There was no 
significant difference in log BNP between baseline and threshold-crossing events 
compared with data for OptiVol 1.0 (2.22 ± 0.46 vs. 2.23 ± 0.47, p = 0.48; Fig. 3A), and 
the incidence of an increase in log BNP was observed in 82 patients (55%). Among the 
150 threshold-crossing events, ITI at threshold crossing was lower than that at baseline 
by 4% for only 46 patients (31%) with OptiVol 1.0. Of the 150 events, the threshold was 
crossed for only 37 (25%) with OptiVol 2.0. Among these 37 events (OptiVol 2.0 
positive group), log BNP was significantly higher at threshold crossing than at baseline 
(2.40 ± 0.46 vs. 2.27 ± 0.52, p = 0.009; Fig. 3B), and the incidence of an increase in log 
BNP was observed in 28 of 37 events (76%). For the remaining 113 events (OptiVol 2.0 
negative group), the fluid index simulated with OptiVol 2.0 did not cross the threshold 
of 60. For this OptiVol 2.0 negative group, there was no significant difference in log 
BNP between baseline and threshold-crossing events (2.20 ± 0.44 vs. 2.18 ± 0.46, p = 
0.16; Fig. 3C), and the incidence of an increase in log BNP was observed in 54 patients 
(48%). 
In the OptiVol 2.0 positive group, ITI at threshold crossing was ≥4% lower 
than at stable baseline for 23 patients (62%), and the remaining 14 events were 
considered as false positives (38%). In the OptiVol 2.0 negative group, ITI at threshold-
crossing was ≥4% lower than at stable baseline in 23 patients (20%), and the remaining 
90 events were considered as false positives (80%). 
Relation to signs of HF 
We compared HF-related parameters between baseline and threshold-crossing events. 
HF-related parameters included body weight, dimension of the inferior vena cava, E-
wave velocity, early-to-late ventricular filling velocities ratio, and the pressure gradient 
of tricuspid regurgitation. We also measured red blood cell count, hemoglobin, 
hematocrit, serum albumin, blood urea nitrogen, total protein, and creatinine (Table 2). 
There were no significant differences in any of these parameters between baseline and 
threshold-crossing events in the OptiVol 2.0 negative group. In the OptiVol 2.0 positive 
group, the dimensions of the inferior vena cava and the E-wave velocity were 
significantly higher. In contrast, red blood cell count, hemoglobin, hematocrit, total 
protein, albumin, blood urea nitrogen, and creatinine levels were significantly lower 
compared with the baseline values. The changes in HF-related parameters indicate fluid 
retention at the threshold-crossing events detected by OptiVol 2.0. 
OptiVol 2.0 and the three false-positive ITI trends 
In the previous study, we identified three typical ITI trends that were often 
associated with false-positive determinations based on OptiVol 1.0. The “cross to 
reference” pattern was found in 56 threshold-crossing events in OptiVol 1.0 without an 
increase in BNP. After analysis with OptiVol 2.0, only 5 (9%) of these 56 events showed 
threshold crossing (91% reduction, p < 0.001; Fig. 4A). The “spontaneous recovery” 
pattern was observed in 59 threshold-crossing events in OptiVol 1.0 without an increase 
in BNP. After analysis with OptiVol 2.0, only 7 (12%) of 59 events showed threshold 
crossing (88% reduction, p = 0.003; Fig. 4B). The third pattern of “temporary elevation” 
was found in 27 threshold-crossing events in OptiVol 1.0, but after the analysis with 
OptiVol 2.0 10 (37%) of the 27 events showed threshold crossing, and OptiVol 2.0 did 
not reduce the false-positive alerts in this ITI pattern (63% reduction, p = 0.14; Fig. 4C). 
Reproducibility of the simulation 
The simulation with OptiVol 2.0 was performed again with the raw ITI data 
from a randomly selected set of 50 patients. The calculated fluid index values from the 
simulation showed strong correlation with the real fluid index values (R = 0.997 ± 
0.001, range: 0.964–1.000, p < 0.001). 
Discussion 
New findings 
Although remote monitoring of ITI trends by an implantable device is expected to 
facilitate early diagnosis of HF before symptoms appear, a high frequency of false-
positive alerts limits the clinical application of this system. In this simulation study, we 
demonstrated a significant reduction in threshold-crossing events, from 150 to 37 events 
(75% reduction), with the modified algorithm. These 37 events were also associated 
with an increase in log BNP compared with the baseline value and changes in laboratory 
and echocardiographic parameters, supporting the determination of fluid accumulation 
at the threshold-crossing events. This modified algorithm was able to discriminate false-
positive events associated with the two typical ITI trends “cross to reference”and 
“spontaneous recovery”. To our knowledge, this is the first study to demonstrate that the 
modified OptiVol 2.0 algorithm can reduce false-positive events and may improve the 
diagnostic potential of this system for early-stage HF. 
Comparison to previous study 
The practicality of remote monitoring of ITI remains controversial because of 
the high false-positive alert rate. Several previous studies have examined the issue of 
false alerts. Van Veldhuisen et al. demonstrated that remote ITI monitoring with the alert 
function increased hospitalizations and outpatient visits owing to false-positive alerts 
[8]. Ypenburg et al. reported that only 33% of the alerts were associated with HF-related 
events in patients with implantable cardioverter defibrillators [11]. Then, the modified 
OptiVol 2.0 algorithm was developed to reduce false-positive alerts. Actually, Sarkar et 
al. reported that the modified algorithm reduces unexplained detections by 30% [12]. 
Our simulation study also demonstrated considerable reduction in threshold-crossing 
events compared with the previous algorithm, and that the remaining threshold-crossing 
events by the modified algorithm were associated with increases in BNP and signs of 
HF indicated by HF parameters. The positive predictive value obtained with OptiVol 2.0 
(76%) was substantially greater than that for OptiVol 1.0 (55%). Therefore, the modified 
algorithm appears to be superior to the previous algorithm for the diagnosis of early-
stage HF. In other words, the modified OptiVol 2.0 algorithm might select only true HF-
related events. 
False positive ITI trends corrected by modified OptiVol 2.0 algorithm 
In our previous study, we identified three ITI trends that were often associated 
with false-positive alerts with the previous algorithm. We found that the modified 
algorithm substantially reduced the threshold-crossing events associated with the “cross 
to reference” and “spontaneous recovery” patterns. However, the modified algorithm 
could not reduce the number of the threshold-crossing events for the “temporary 
elevation” pattern. For this pattern, ITI shows a gradual reduction to baseline level after 
a relatively long period of increase, which is associated with an increase in the reference 
curve. This ITI trend is often observed in patients experiencing dehydration or with 
increasing doses of diuretics [13]. In this situation, it is important to consider the change 
in ITI values from baseline. If the values do not decrease by ≥4% compared with 
baseline, these threshold-crossing events may be false-positives. 
Clinical implication of modified OptiVol 2.0 algorithm 
It is difficult to diagnose impending HF before symptoms appear in clinical 
settings. Stevenson et al. reported that physical examination often fails to detect 
elevated LV filling pressures in patients with chronic HF [14]. Monitoring body weight 
and symptoms with telephone interviews also failed to reduce HF hospitalization. Yu et 
al. retrospectively analyzed the temporal relationship between ITI decrease and clinical 
symptoms related to HF. They found that the time interval between the start of ITI 
decrease and HF-related symptoms was significantly longer than that between HF-
related symptoms and HF hospitalization (15.3 ± 10.6 vs. 3.0 ± 2.5 days, p < 0.001) [5]. 
In our study, log BNP values in the OptiVol 2.0 positive group were significantly higher 
at OptiVol alert than that at baseline. On the other hand, patients in the OptiVol 2.0 
negative group were not associated with HF-related symptoms or clinical signs of HF 
deterioration. Therefore, the modified algorithm may be effective in selecting patients 
with early-stage HF. 
Study limitations 
This study has several limitations. First, this study is a simulation, and a prospective 
clinical study is required to conclude whether the modified algorithm reduces false-
positive events. However, the modified algorithm was able to reduce the false-positive 
events in the same ITI trends compared with the previous algorithm for the same raw 
ITI data. Second, it is also important to reduce false-negative events for the accurate 
diagnosis of HF, but our study did not examine whether the modified algorithm reduced 
false-negative events because we did not retain the raw ITI data for patients with HF 
hospitalization without threshold-crossing events. Finally, ITI is affected by many 
factors other than fluid retention, such as pocket infection, pneumonia, and anemia. The 
diagnostic potential of the new algorithm has not been determined under these 
pathological conditions. 
Conclusions 
ITI monitoring with the modified OptiVol 2.0 algorithm may represent a new and 
promising way to detect impending HF with increased reliability compared with the 
previous OptiVol 1.0 algorithm. Device-based diagnostics could be helpful as an adjunct 
tool. 
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Tables 
Table 1 Patient characteristics at baseline 
Data given as mean ± SD. 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain 
natriuretic peptide; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; 
NYHA, New York Heart Association. 
Table 2 Secondary endpoints at baseline and each OptiVol alert 
Data given as mean ± SD. 
Alb, albumin; BUN, blood urea nitrogen; Cre, creatinine; E/A ratio, early-to-late 
ventricular filling velocities; Hb, hemoglobin; Ht, hematocrit; IVC (E), dimension of 
the inferior vena cava at expiration; IVC (I), dimension of the inferior vena cava at 
inspiration; RBC, red blood cells; TP, total protein; TRPG, pressure gradient of tricuspid 
regurgitation. 
Figure legends 
Figure 1 Intrathoracic impedance trends associated with false-positive events. (A) 
“cross to reference,” (B) “spontaneous recovery,” and (C) “temporary elevation” 
patterns. 
Figure 2 Comparison of simulation analysis with OptiVol 2.0 and OptiVol 1.0. The 
blue-shaded area shows an event in which the fluid index threshold was crossed in 
OptiVol 1.0 but not OptiVol 2.0, and BNP was not different between the baseline and 
OptiVol 1.0 alert (246.0 vs. 257.0 pg/ml). The orange-shaded area shows an event in 
which the threshold was crossed in both OptiVol 1.0 and 2.0, and BNP was higher at the 
OptiVol alert than at baseline (246.0 vs. 487.9 pg/ml). 
BNP, brain natriuretic peptide. 
Figure 3 Differences in log BNP between baseline and OptiVol alerts. (A) There was 
no significant difference in log BNP between baseline and OptiVol 1.0 alerts (N = 150, 
p = 0.48). (B) Log BNP was significantly higher at OptiVol alerts in the OptiVol 2.0 
positive group than at baseline (N = 37, 2.27 ± 0.52 vs. 2.40 ± 0.46, p = 0.009). (C) 
There was no significant difference in log BNP between baseline and OptiVol alerts in 
the OptiVol 2.0 negative group (N = 113, p = 0.16). 
BNP, brain natriuretic peptide. 
Figure 4 Comparison of the three types of alert events between OptiVol 2.0 and 
OptiVol 1.0. (A) “cross to reference,” (B) “spontaneous recovery,” and (C) “temporary 
elevation” patterns. 



